Literature DB >> 21411460

Endovascular treatment of acute limb ischemia: review of current plasminogen activators and mechanical thrombectomy devices.

Sean P Lyden1.   

Abstract

Acute limb ischemia occurs in 15% to 20% of patients with chronic peripheral arterial disease. Off-label use of tissue plasminogen activators is the most common approach for patients with ischemic limbs that can wait 24 to 48 hours to restore flow. In the past decade, mechanical thrombectomy devices that use aspiration, maceration, or ultrasound waves have been developed to allow more rapid restoration of flow. Combination therapy with both mechanical and pharmacologic thrombolysis has become commonplace without randomized data to support its use. This article reviews acute limb ischemia and data regarding pharmacologic and mechanical thrombolysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21411460     DOI: 10.1177/1531003511400624

Source DB:  PubMed          Journal:  Perspect Vasc Surg Endovasc Ther        ISSN: 1521-5768


  3 in total

1.  Pulsed high-intensity-focused US and tissue plasminogen activator (TPA) versus TPA alone for thrombolysis of occluded bypass graft in swine.

Authors:  Nadine Abi-Jaoudeh; William F Pritchard; Hayet Amalou; Marius Linguraru; Oscar A Chiesa; Joshua D Adams; Carmen Gacchina; Robert Wesley; Subha Maruvada; Briana McDowell; Victor Frenkel; John W Karanian; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2012-05-19       Impact factor: 3.464

2.  Endovascular versus surgical treatment for acute limb ischemia: a systematic review and meta-analysis of clinical trials.

Authors:  Tariq H Enezate; Jad Omran; Ehtisham Mahmud; Mitul Patel; Mazen S Abu-Fadel; Christopher J White; Ashraf S Al-Dadah
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

3.  Increasing injection frequency enhances the survival of injected bone marrow derived mesenchymal stem cells in a critical limb ischemia animal model.

Authors:  Woong Chol Kang; Pyung Chun Oh; Kyounghoon Lee; Taehoon Ahn; Kyunghee Byun
Journal:  Korean J Physiol Pharmacol       Date:  2016-10-28       Impact factor: 2.016

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.